Company attributes
Other attributes
Bluebird Bio, formerly Genetix Pharmaceuticals, is a biotechnology company developing multiple therapies for the treatment of genetic diseases and cancer that is headquartered in Cambridge, Massachusetts and was founded in 1993 by Philippe Leboulch. The company is developing gene addition therapies, gene editing therapies, and cancer immunotherapies for treating a variety of health conditions.
Introduction to Bluebird Bio.
On June 17, 2004 Bluebird Bio completed their series A funding round with $8.5 million in funding from Nazem and Company and ABN AMRO Fund.
On October 7, 2004 Bluebird Bio completed a venture funding round with $12 million in funding from Techno Venture Management (lead investor), Easton Capital, and ABN AMRO Fund.
On March 12, 2010 Bluebird Bio completed their series B funding round with $35 million in funding from Third Rock Ventures (lead investor), Sanofi-Genzyme BioVentures (lead investor), TVM Capital, Forbion Capital Partners, and Easton Capital.
In 2011 Bluebird Bio received a grant worth $9.3 million from The California Institute of Regenerative Medicine (CIRM) to fund their Phase I/II study of LentiGlobin for the treatment of inherited betea-thalas-semia.
On April 20, 2011 Bluebird Bio completed their second venture funding round with $30 million in funding from ARCH Venture Partners (lead investor), Third Rock Ventures, Forbion Capital Partners, TVM Capital, and Easton Capital.
On July 25, 2012 Bluebird Bio completed their series D funding round with $60 million in funding from Third Rock Ventures, TVM Capital, Ramius Capital, RA Capital Management, Forbion Capital Partners, Deerfield Partners, and ARCH Venture Partners.
On December 7, 2016 Bluebird Bio raised $250 million in post-IPO equity.
